-
1دورية أكاديمية
المؤلفون: Karadurmus, N., Bekoz, H., Paydas, S., Turker, A., Toptas, T., Tuglular, T. Firatli, Sonmez, M., Gulbas, Z., Tekgunduz, E., Kaya, A. H., Ozbalak, M., Tastemir, N., Kaynar, L., Karadogan, I., Arat, M., Tanrikulu, F. Pepedil, Ozkocaman, V., Abali, H., Turgut, M., Yuksel, M. Kurt, Ozcan, M., Dogu, M. H., Hacioglu, S. Kabukcu, Barista, I., Demirkaya, M., Koseoglu, F. D., Toprak, S. K., Yilmaz, M., Demirkurek, H. C., Demirkol, O., Ferhanoglu, B., Yildirim, R.
مصطلحات موضوعية: resistant/relapsed disease, Hodgkin lymphoma, programmed death 1 (PD-1) blocker, nivolumab
العلاقة: Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Annals of Oncology; https://hdl.handle.net/11454/31649Test; https://doi.org/10.1093/annonc/mdx341Test; 28; 10; 2496; 2502
-
2دورية أكاديمية
المؤلفون: Bekoz, H., Karadurmus, N., Paydas, S., Turker, A., Toptas, T., Tuglular, T. Firatli, Sonmez, M., Gulbas, Z., Tekgunduz, E., Kaya, A. H., Ozbalak, M., Tastemir, N., Kaynar, L., Yildirim, R., Karadogan, I., Arat, M., Tanrikulu, F. Pepedil, Ozkocaman, V., Abali, H., Turgut, M., Yuksel, M. Kurt, Ozcan, M., Dogu, M. H., Hacioglu, S. Kabukcu, Barista, I., Demirkaya, M., Koseoglu, F. D., Toprak, S. K., Yilmaz, M., Demirkurek, H. C., Demirkol, O., Ferhanoglu, B.
المساهمون: Ege Üniversitesi
مصطلحات موضوعية: Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1) blocker, nivolumab
العلاقة: Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Annals of Oncology; https://doi.org/10.1093/annonc/mdx341Test; https://hdl.handle.net/11454/31649Test; 28; 10; 2496; 2502
-
3دورية أكاديمية
المؤلفون: KaradurmuÅŸ, N., Beköz, H., PaydaÅŸ, S., Türker, A., ToptaÅŸ, T., Firatli TuÄŸlular, T., Sönmez, M.
مصطلحات موضوعية: steroid, antibody conjugate, nivolumab, programmed death 1 receptor, Hodgkin lymphoma, Programmed death 1 (PD-1) blocker, Resistant/relapsed disease, brentuximab vedotin, mycophenolate mofetil, antineoplastic agent, monoclonal antibody, abdominal pain, adult, aged, allergic encephalitis, allogeneic stem cell transplantation, anemia, arthritis, Article, cancer growth, cancer mortality, cancer pain, cancer recurrence, cancer survival, chronic graft versus host disease, controlled study, decreased appetite, diarrhea, drug efficacy, drug response
العلاقة: Annals of Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/9317Test; https://doi.org/10.1007/s00277-020-04077-4Test; 28; 10; 2496; 2502; 2-s2.0-85086129098; WOS:000538693900001
-
4دورية أكاديمية
المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000
مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid
وصف الملف: application/pdf
العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10
الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test -
5دورية أكاديمية
المؤلفون: Bekoz H., Ozbalak M., Karadurmus N., Paydas S., Turker A., Toptas T., Gulbas Z.
مصطلحات موضوعية: Hodgkin lymphoma, Nivolumab, Programmed death 1 (PD-1) blocker, Resistant/relapsed disease
العلاقة: Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Annals of Hematology; https://doi.org/10.1007/s00277-020-04077-4Test; https://hdl.handle.net/11454/71048Test; 99; 11; 2565; 2576
-
6
المؤلفون: Bekoz H., Ozbalak M., Karadurmus N., Paydas S., Turker A., Toptas T., Ferhanoglu B.
المساهمون: Ondokuz Mayıs Üniversitesi
مصطلحات موضوعية: Nivolumab, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Hodgkin lymphoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______9773::cf7c9733af705f42ed063b1bfccda550Test
https://doi.org/10.1007/s00277-020-04077-4Test -
7
المؤلفون: H. Beköz, N. Karadurmuş, S. Paydaş, A. Türker, T. Toptaş, T. Fıratlı Tuğlular, M. Sönmez, Z. Gülbaş, E. Tekgündüz, A.H. Kaya, M. Özbalak, N. Taştemir, L. Kaynar, R. Yıldırım, I. Karadoğan, M. Arat, F. Pepedil Tanrıkulu, V. Özkocaman, H. Abalı, M. Turgut, M. Kurt Yüksel, M. Özcan, M.H. Doğu, S. Kabukçu Hacıoğlu, I. Barışta, M. Demirkaya, F.D. Köseoğlu, S.K. Toprak, M. Yılmaz, H.C. Demirkürek, O. Demirkol, B. Ferhanoğlu
المساهمون: Acibadem University Dspace, OMÜ, Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, Çukurova Üniversitesi, Ege Üniversitesi, İç Hastalıkları
المصدر: Annals of Oncology. 28:2496-2502
مصطلحات موضوعية: cancer pain, allograft, Hypophosphatemia, retrospective study, thrombocytopenia, Septic shock, middle aged, immunopathology, Medicine, Disease free survival, catheter infection, progression free survival, Hematology, adult, steroid, clinical trial, Chronic graft versus host disease, nausea, Allografts, Survival Rate, Clinical trial, aged, priority journal, Oncology, drug withdrawal, Photopheresis, 030220 oncology & carcinogenesis, medicine.medical_specialty, gynecomastia, muscle cramp, Major clinical study, visual disorder, Article, 03 medical and health sciences, Hypothyroidism, brentuximab vedotin, neutropenia, Cancer recurrence, Retrospective Studies, Aged, hypophosphatemia, treatment response, Upper respiratory tract infection, major clinical study, Resistant, drug efficacy, multicenter study, Pancreatitis, monoclonal antibody, fatigue, drug safety, peripheral neuropathy, Immunoconjugates, drug response, pancreatitis, PD-1 blockade, rash, hypocalcemia, allogeneic stem cell transplantation, immune system diseases, hemic and lymphatic diseases, Monoclonal, Edema, pain, Overall survival, Visual disorder, Cancer pain, appetite disorder, Fatigue, Priority journal, treatment withdrawal, Hodgkin Disease, Programmed death 1 receptor, photopheresis, arthritis, scrotal pain, young adult, Gynecomastia, medicine.drug, Adult, Abdominal pain, Neutropenia, chronic graft versus host disease, side effect, Adolescent, overall survival, Drug response, Pain, overall response rate, macromolecular substances, Relapsed Disease, Rash, Refractory Hodgkin Lymphoma, hyperthyroidism, pneumonia, Stomatitis, Hypocalcemia, business.industry, Pruritus, allergic encephalitis, mycophenolate mofetil, hypercalcemia, programmed death 1 receptor, pruritus, Cancer survival, Allogeneic stem cell transplantation, Surgery, Drug efficacy, Graft versus host reaction, cancer recurrence, classical Hodgkin lymphoma, septic shock, edema, Hodgkin lymphoma, 030215 immunology, Male, encephalitis, diarrhea, Agent, sepsis, phlebitis, 0302 clinical medicine, infusion related reaction, cancer survival, Drug safety, Brentuximab vedotin, disease free survival, Antibody conjugate, autoimmune liver disease, Stem cell transplantation, Headache, Antibodies, Monoclonal, Scrotal pain, General Medicine, cohort analysis, anemia, Antineoplastic, Multicenter study, Retrospective study, Nivolumab, named patient program, Infection, Human, Diarrhea, resistant/relapsed disease, heart infarction, Antineoplastic Agents, Cancer mortality, Disease-Free Survival, cancer growth, multiple cycle treatment, Humans, human, autoimmune pneumonitis, Adverse effect, cystitis, Steroid, nivolumab, cancer immunotherapy, Brentuxımab vedotın, Chlorambucil, Arthritis, abdominal pain, Pneumonia, medicine.disease, mortality, infection, Retrospective studies, Graft-versus-host disease, lymphocytopenia, upper respiratory tract infection, Hypercalcemia, Muscle cramp, drug hypersensitivity, lung disease, Peripheral neuropathy, antibody conjugate, Turkey (republic), cancer mortality, Middle aged, antineoplastic agent, fever, Allergic encephalitis, Mycophenolate mofetil, Antibodies, Monoclonal/*therapeutic use, Antineoplastic Agents/therapeutic use, Brentuximab Vedotin, Female, Hodgkin Disease/*drug therapy/therapy, Immunoconjugates/therapeutic use, Middle Aged, Stem Cell Transplantation, Young Adult, Anemia, female, Decreased appetite, Encephalitis, headache, Hodgkin's Disease, Refractory Materials, Monoclonal antibody, Hodgkin disease, Fever, Disease-free survival, stem cell transplantation, Hypertransaminasemia, Antibodies, programmed death 1 (PD-1) blocker, Internal medicine, follow up, controlled study, decreased appetite, dermatitis, graft versus host reaction, Lymphocytopenia, hypertransaminasemia, Agents, Thrombocytopenia, stomatitis, Transplantation, Young adult, Lung disease, Progression free survival, Infusion related reaction, hypothyroidism, business, Controlled study, Follow-Up Studies
وصف الملف: application/pdf; text/plain
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724de343bc2ead3c22e0218984e89226Test
https://doi.org/10.1093/annonc/mdx341Test -
8
المؤلفون: Bekoz, H, Karadurmus, N, Paydas, S, Turker, A, Toptas, T, Tuglular, TF, Sonmez, M, Gulbas, Z, Tekgunduz, E, Kaya, AH, Ozbalak, M, Tastemir, N, Kaynar, L, Yildirim, R, Karadogan, I, Arat, M, Tanrikulu, FP, Ozkocaman, V, Abali, H, Turgut, M, Yuksel, MK, Ozcan, M, Dogu, MH, Hacioglu, SK, Barista, I, Demirkaya, M, Koseoglu, FD, Toprak, SK, Yilmaz, M, Demirkurek, HC, Demirkol, O, Ferhanoglu, B
مصطلحات موضوعية: blocker, nivolumab, Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1)
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::41a93b1efc07a4e851ef608091a28bf9Test
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/15718Test